| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,330,000 |
| Market
Cap: |
137.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9801 - $5.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. Co. has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats technology and it continues to expand its capabilities. Co. is developing in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, ex vivo gene-edited cell medicines, in which cells collected from a patient are edited with Co.'s technology and then administered back to that same patient, and cellular therapy medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
45,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$253,868 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
16,364 |
39,996 |
62,733 |
202,123 |
| Total Sell Value |
$28,217 |
$68,645 |
$179,055 |
$1,352,683 |
| Total People Sold |
3 |
4 |
5 |
6 |
| Total Sell Transactions |
3 |
6 |
12 |
24 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Parison Amy |
SVP, Chief Financial Officer |
• – – |
2025-06-03 |
4 |
S |
$1.72 |
$769 |
D/D |
(446) |
17,506 |
|
-25% |
|
| Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
• – – |
2025-06-03 |
4 |
S |
$1.72 |
$1,252 |
D/D |
(726) |
69,519 |
|
-25% |
|
| Oneill Gilmore Neil |
CEO |
• • – |
2025-06-03 |
4 |
S |
$1.72 |
$26,196 |
D/D |
(15,192) |
280,282 |
|
-25% |
|
| Parison Amy |
SVP, Chief Financial OfficerOf |
• – – |
2025-03-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,952 |
|
82% |
|
| Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
• – – |
2025-03-04 |
4 |
S |
$1.71 |
$4,946 |
D/D |
(2,891) |
70,245 |
|
-30% |
|
| Lucera Erick |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2025-03-04 |
4 |
S |
$1.71 |
$7,030 |
D/D |
(4,109) |
112,720 |
|
-30% |
|
| Oneill Gilmore Neil |
CEO |
• • – |
2025-03-04 |
4 |
S |
$1.71 |
$28,452 |
D/D |
(16,632) |
295,474 |
|
-30% |
|
| Oneill Gilmore Neil |
CEO |
• • – |
2024-12-03 |
4 |
S |
$2.08 |
$3,361 |
D/D |
(1,618) |
312,106 |
|
32% |
|
| Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
• – – |
2024-12-03 |
4 |
S |
$2.08 |
$1,124 |
D/D |
(541) |
133,354 |
|
32% |
|
| Oneill Gilmore Neil |
CEO |
• • – |
2024-09-04 |
4 |
S |
$3.42 |
$5,325 |
D/D |
(1,555) |
313,724 |
|
67% |
|
| Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
• – – |
2024-09-04 |
4 |
S |
$3.42 |
$1,774 |
D/D |
(518) |
133,895 |
|
67% |
|
| Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
• – – |
2024-07-25 |
4 |
S |
$5.42 |
$64,370 |
D/D |
(11,886) |
73,136 |
|
64% |
|
| Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
• – – |
2024-07-19 |
4 |
S |
$5.21 |
$34,456 |
D/D |
(6,619) |
134,413 |
|
56% |
|
| Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
• – – |
2024-06-04 |
4 |
S |
$5.50 |
$2,808 |
D/D |
(511) |
141,032 |
|
44% |
|
| Oneill Gilmore Neil |
CEO |
• • – |
2024-06-04 |
4 |
S |
$5.50 |
$66,997 |
D/D |
(12,191) |
315,279 |
|
44% |
|
| Lucera Erick |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-05-20 |
4 |
S |
$5.61 |
$125,404 |
D/D |
(22,337) |
116,829 |
|
38% |
|
| Hopfield Jessica |
Director |
– • – |
2024-05-13 |
4 |
B |
$5.64 |
$253,868 |
D/D |
45,000 |
67,700 |
2.39 |
-36% |
|
| Oneill Gilmore Neil |
CEO |
• • – |
2024-03-05 |
4 |
S |
$9.42 |
$732,884 |
D/D |
(77,824) |
327,470 |
|
35% |
|
| Mei Baisong |
SVP, CHIEF MEDICAL OFFICER |
• – – |
2024-03-04 |
4 |
S |
$9.42 |
$191,425 |
D/D |
(20,327) |
141,543 |
|
43% |
|
| Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
• – – |
2024-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
39,855 |
85,022 |
|
- |
|
| Lucera Erick |
EVP, CHIEF FINANCIAL OFFICER |
• – – |
2024-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
61,266 |
139,166 |
|
- |
|
| Oneill Gilmore Neil |
CEO |
• • – |
2024-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
275,125 |
405,294 |
|
- |
|
| Mei Baisong |
SVP, CHIEF MEDICAL OFFICER |
• – – |
2024-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
89,815 |
161,870 |
|
- |
|
| Eaton Bruce |
EVP, CBO AND CTO |
• – – |
2023-12-05 |
4 |
S |
$10.90 |
$1,122 |
D/D |
(103) |
74,791 |
|
47% |
|
| Eaton Bruce |
EVP, CBO AND CTO |
• – – |
2023-11-14 |
4 |
S |
$8.21 |
$5,706 |
D/D |
(695) |
74,894 |
|
15% |
|
276 Records found
|
|
Page 1 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.08 (3.51%) 
